All In Biotech

Drug Trial Radar · NCT01499277

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities

Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

802

Actual

Start

May 2012

Primary completion

Jun 2014

Study completion Jan 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
Dec 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.

Conditions

  • Complicated Skin and Soft Tissue Infection

Interventions

  • Ceftaroline fosamilDrug

    IV ceftaroline 600mg every 8 hours

  • VancomycinDrug

    IV vancomycin 15mg/kg every 12 hours

  • AztreonamDrug

    IV aztreonam 1 g every 8 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis SetTime frame: 7 to 20 days after the last dose of study drug
  2. Clinical Response at TOC in Clinically Evaluable (CE) Analysis SetTime frame: 7 to 20 days after the last dose of study drug

Locations

91 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Chula Vista, California

  • Research Site

    Orlando, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Carmel, Indiana

  • Research Site

    Hazard, Kentucky

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Garden City, New York

  • Research Site

    Bellaire, Texas

  • Research Site

    Córdoba, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Parkville, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Passo Fundo, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Temuco, Chile

  • Research Site

    Viña del Mar, Chile

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Haikou, China

  • Research Site

    Nanning, China

  • Research Site

    Qingdao, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shijiazhuang, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Slavonski Brod, Croatia

  • Research Site

    Zagreb, Croatia

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.